Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(40%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Recruiting1
Completed1
Terminated1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

recruiting120%
completed120%
terminated120%
active_not_recruiting120%
not_yet_recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_1

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

NCT05518045
completedphase_1

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

NCT05199753
not_yet_recruitingphase_2

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

NCT06873854
recruitingphase_2

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

NCT06387628
terminatedphase_1

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

NCT05255484

Clinical Trials (5)

Showing 5 of 5 trials
NCT05518045Phase 1

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Active Not Recruiting
NCT05199753Phase 1

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Completed
NCT06873854Phase 2

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Not Yet Recruiting
NCT06387628Phase 2

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Recruiting
NCT05255484Phase 1

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5